BidaskClub upgraded shares of Cardiovascular Systems (NASDAQ:CSII) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning.

CSII has been the subject of several other research reports. ValuEngine upgraded shares of Cardiovascular Systems from a hold rating to a buy rating in a research report on Friday, July 6th. Zacks Investment Research lowered shares of Cardiovascular Systems from a buy rating to a hold rating in a research report on Friday, August 3rd. Stifel Nicolaus started coverage on shares of Cardiovascular Systems in a research report on Wednesday, August 22nd. They set a buy rating and a $45.00 price target for the company. Lake Street Capital restated a buy rating and set a $50.00 price target on shares of Cardiovascular Systems in a research report on Wednesday, August 1st. Finally, Bank of America upgraded shares of Cardiovascular Systems from an underperform rating to a buy rating in a research report on Wednesday, June 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. Cardiovascular Systems has a consensus rating of Hold and an average target price of $35.20.

NASDAQ CSII opened at $39.10 on Wednesday. Cardiovascular Systems has a 1 year low of $20.58 and a 1 year high of $39.50. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.47 and a quick ratio of 4.03. The firm has a market capitalization of $1.31 billion, a PE ratio of 784.40 and a beta of 2.45.

Cardiovascular Systems (NASDAQ:CSII) last posted its earnings results on Monday, July 30th. The medical device company reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.05. Cardiovascular Systems had a net margin of 0.79% and a return on equity of 1.36%. The firm had revenue of $59.15 million during the quarter, compared to analyst estimates of $58.43 million. analysts forecast that Cardiovascular Systems will post -0.07 earnings per share for the current fiscal year.

In other Cardiovascular Systems news, CFO Jeffrey S. Points sold 971 shares of the company’s stock in a transaction dated Friday, August 17th. The shares were sold at an average price of $37.54, for a total transaction of $36,451.34. Following the sale, the chief financial officer now directly owns 23,229 shares of the company’s stock, valued at $872,016.66. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Scott R. Ward acquired 2,500 shares of the company’s stock in a transaction on Wednesday, August 29th. The shares were acquired at an average cost of $38.39 per share, for a total transaction of $95,975.00. Following the completion of the acquisition, the chief executive officer now owns 278,362 shares of the company’s stock, valued at $10,686,317.18. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 3,177 shares of company stock valued at $119,274. 3.30% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Champlain Investment Partners LLC lifted its holdings in shares of Cardiovascular Systems by 15.0% in the first quarter. Champlain Investment Partners LLC now owns 2,590,330 shares of the medical device company’s stock worth $56,806,000 after buying an additional 336,975 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Cardiovascular Systems by 9.3% in the second quarter. BlackRock Inc. now owns 2,479,543 shares of the medical device company’s stock worth $80,188,000 after buying an additional 210,128 shares in the last quarter. Partner Fund Management L.P. lifted its holdings in shares of Cardiovascular Systems by 49.9% in the second quarter. Partner Fund Management L.P. now owns 1,230,921 shares of the medical device company’s stock worth $39,808,000 after buying an additional 409,767 shares in the last quarter. Cortina Asset Management LLC lifted its holdings in shares of Cardiovascular Systems by 8.6% in the first quarter. Cortina Asset Management LLC now owns 841,013 shares of the medical device company’s stock worth $18,443,000 after buying an additional 66,768 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Cardiovascular Systems by 187.0% in the second quarter. FMR LLC now owns 516,100 shares of the medical device company’s stock worth $16,690,000 after buying an additional 336,300 shares in the last quarter. 84.56% of the stock is currently owned by institutional investors and hedge funds.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.

Further Reading: How to Track your Portfolio in Google Finance

Analyst Recommendations for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.